Our new study on trends and correlates of ketamine use 2015-2022 in Journal of Affective Disorders: past-year ketamine use ⬆️82% (2015-2019) and ⬆️40% (2021-2022). Recent increases were only significant in non-depressed adults. @wkepner @JosephPalamar

4/ Results suggest cannabis impacts workplace attendance beyond just those with CUD. More long-term and qualitative studies are needed to better understand these associations.

Excited to contribute to @MedscapePsych's recent piece on #psychedelics and #microdosing. It's crucial for clinicians to navigate patient questions on this topic. Great insights from @Peter_Grinspoon and @RachelYehuda as well.

RT @Peter_Grinspoon: Huge increase in interest in #microdosing #psychedelics in this @JAMA_current article (I wrote blog about microdosing…

6/ As decriminalization/legalization continue, studying microdosing's benefits & risks is crucial. Adverse events highlight the urgent need for evidence to inform policy & public health. See:

RT @wkepner: Unregulated sales of Amanita Muscaria pose serious health risks. Urgent need for public health measures to address this issue.…

Our new research letter is out in @AGSJournal identifying correlates of cannabis use among middle-aged and older adults! @NSatybaldiyeva @jnbergstrom @AlisonMooreMD @UCSDMedSchool @UCSDGeriatrics

Our latest paper analyzing 2015-2019 NSDUH data: we found that #cannabis use is increasing more rapidly among adults with certain disabilities and kidney disease @NSatybaldiyeva @wkepner @benhhan @AlisonMooreMD @JosephPalamar @UCSDMedSchool

RT @PamBelluck: NEW: In a first, the F.D.A. approved a pill for postpartum depression. The drug, zuranolone, acts faster than other antidep…

Phase 1 trial of psilocybin for anorexia with encouraging results @NatureMedicine. Grateful to have been a part of this project! Congrats to @UCSD_EDC. @UCSDHealthSci @PsychiatryUcsd

RT @NaturePortfolio: A trial reported in @NatureMedicine finds that a dose of the psychedelic psilocybin administered with psychological su…

RT @EricTopol: Not every day you see an anti-obesity drug that has an average of >24% body weight loss 🆕 @NEJM #ADA2023